BeEAM Versus CEM in Lymphoma Patients as a Conditioning Regimen Before Autologous Hematopoietic Cell Transplantation

• Status: Recruiting
• Trial end date: 2023-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The proposed research aims to compare between BeEAM standard regimen and CEM as conditioning regimen in lymphoma patients in safety profile& toxicity, infections (Febrile neutropenia) during transplant, time to engraftment (recovery not neutropenic), Length of stay at hospital, time to relapse, and other complications.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Rehab Werida
• Treatments: Bendamustine Hydrochloride; Carboplatin; Cytarabine; Etoposide; Etoposide phosphate; Melphalan

Criteria

Inclusion Criteria

1. Patients with lymphoma relapsed/refractory (RR) Hodgkin's lymphoma (HL) and non-Hodgkin lymphoma (NHL) with all subtypes. 2. Treat with conventional dose salvage regimens 3. Remission status before HSCT is complete remission (CR) or partial remission (PR).

4. Age>18 years. 5. Gender male and female. 6. CD34+ count cells <2 ×106 CD34+ cells/kg BW. Exclusion Criteria

1. Remission status before HSCT is non remission (NR) or progressive disease (PD).

2. CD34+ count cells <2 ×106 CD34+ cells/kg BW

3. CNS lymphoma or solid tumor not included in population.

4. Pregnancy or breast-feeding.

5. Any Psychological, familial, sociological, or geographical factor that interfere with patient adherence to medications.

6. History of allergy to any medications in both protocol